Safety and Efficacy of Daratumumab in Combination With Ixazomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

NCT03746652 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Daratumumab, Ixazomib, Dexamethasone

Sponsor

Hellenic Society of Hematology

Collaborators

[object Object]
[object Object]